Episode Details

Mettler-Toledo International Inc. (MTD) Q2 2026 — Reported after the close on July 30 (calendar Q2 ended June 30, 2026). Net sales $1,027.3M (+4.5% reported, +6% local currency ex a one-time customer tariff refund, +4% organic); adjusted EPS $11.46 vs ~$10.79 expected (+14%); GAAP diluted EPS $11.55 — higher than the adjusted figure; FY26 guidance raised to $47.15-$47.50. The stock rose 2.59% to $1,416.30 on July 31. The line nobody printed: free cash flow was $801M in 2021 and $849M in 2025 — 1.5% a year — while free cash flow per share compounded at 4.7%. Sixty-eight percent of the per-share growth is the shrinking share count, not the business. THE CALL: AVOID (3/5, GREAT BUSINESS, FOUR YEARS OF FLAT CASH) — base-case value ~$815.0 vs ~$1416.3 today. KEY METRICS: - CALL: AVOID 3/5 — fair value ~$815 vs $1,416.30 (-42%). Owner-earnings DCF: FY26E adj. FCF ~$857M less $22M stock comp = $835M; +6%/yr for 5 years then 4%, 2.5% terminal at 8.25% = $807/sh (EV $18.23B less $2.06B net debt / 20.04M shares). Bear $608, bull $1,029, prob-weighted $813. - STREET: Hold — 8 buy / 11 hold / 0 sell (19 analysts). Average target $1,416.50 against a $1,416.30 close: ZERO upside. Post-print Jefferies upgraded to Buy at $1,580; the low is Baird at $1,194. We ALIGN on the conclusion but are far more CAUTIOUS on the number. - THE QUARTER WAS GOOD: net sales $1,027.3M (+4.5%; +6% local ccy ex-tariff refund, +4% organic). Adjusted EPS $11.46 (+14%) beat ~$10.79. Adjusted operating profit $309.3M at 29.3% (+50bps). Guidance RAISED: FY26 adj. EPS $47.15-$47.50; Q3 $12.00-$12.15. - THE MARGIN DID NOT REALLY EXPAND: reported gross margin 63.3% vs 59.0% contains a one-time $52.4M IEEPA tariff refund booked as a REDUCTION OF COST OF SALES, less $27.8M refunded to customers. Underlying: 59.3% vs 59.0% — 30bps, not 430. Cost of sales FELL 6.5% while revenue rose 4.5%. Management excluded the $24.6M net benefit, which is why adjusted EPS sits BELOW GAAP. - THE BUYBACK IS DOING 68% OF THE WORK: free cash flow was $801M (2021), $738M, $861M, $864M, $849M (2025) — 1.5%/yr. Diluted shares fell 23.46M to 20.67M, so FCF PER SHARE grew 4.7%/yr: 1.5 points business, 3.2 points share count. The buyback is shrinking ($1,100M in 2022 to $800M) and H1 repurchases of $420.1M were 115% of adjusted FCF. - THE PREMIUM FRANCHISE IS THE SLOW ONE: Laboratory (55% of sales) grew just 2.7% to $552.6M; Industrial (40%) +5.8%; Food Retail (5%) +12.6%. The Americas FELL 2.8%, Europe +7.2%, Asia/RoW +12.3%. Organic local currency: Americas +1%, Europe +4%, Asia/RoW +9%. - CHINA IS THE PROFIT ENGINE: of $333.9M of segment profit, Chinese Operations earned $102.1M (30.6%) — more than Swiss ($68.9M) and Western European ($48.9M) COMBINED — at a 37.1% margin vs 25.8% and 17.7%, on just $0.7M of goodwill. Chinese profit +14.3%; Swiss -2.4%; W. European -5.7%. - BALANCE SHEET: equity is $12.8M on $3,671M of assets ($10.26B of treasury stock); net debt $2,060.6M, ~1.6x EBITDA. H1 adjusted FCF fell 10.3% to $366.7M while adjusted EPS rose 11%. At $1,416.30 that is 29.9x guided FY26 EPS and 36.5x owner earnings; the reverse DCF demands 12.7%/yr for five years against 1.5% delivered since 2021. What to watch: Bullish: adjusted free cash flow growing above 6% for two or three straight quarters, and laboratory growth above 5%. Bearish: FY2026 adjusted free cash flow at or below 2025's $849M (a fifth flat year), or the buyback dropping under ~$700M a year. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.